Physician profile
Bob Winston
NPI 1619064367
$6,150.51
in general payments reported to CMS, 2019-2025
28 companies · $892 in 2025
The $892 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $611 · 2021: $838 · 2022: $1,000 · 2023: $838 · 2024: $1,308 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,139.10 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,121.35 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $712.61 | 2019-2022 | |
| Alkermes, INC. | $494.03 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $428.59 | 2019-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $313.28 | 2022-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.12 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $262.90 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $262.88 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $188.61 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $157.42 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $143.00 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $118.37 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.34 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $65.92 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $46.51 | 2023 | |
| Indivior INC. | $39.74 | 2023-2024 | Perseris, Sublocade |
| Bausch Health US, LLC | $36.59 | 2022 | |
| Neos Therapeutics, LP | $35.18 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $32.68 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $24.34 | 2020 | |
| Adlon Therapeutics L.P. | $21.89 | 2020 | |
| Neuronetics, INC. | $20.43 | 2019 | |
| Corium, LLC | $18.54 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $15.74 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.64 | 2019 | |
| Merck Sharp & Dohme LLC | $12.39 | 2019 | |
| Eisai INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.